Moderate Evidence
Research Overview
Zelenectide Pevedotin Research for Metastatic Urothelial Carcinoma
An overview of research and source records on Zelenectide Pevedotin in the context of metastatic urothelial carcinoma.
Research Summary
Primary indication with Phase 1/2 clinical data. In the Duravelo-1 dose-escalation study, urothelial carcinoma patients (median three prior lines of therapy) had a 38% objective response rate (8/21) and a 57% clinical benefit rate, with an 11.1 month median duration of response. Phase 2/3 Duravelo-2 registrational trial ongoing.
References
Open a reference to inspect its source record. A citation does not establish a clinical benefit.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.